: $0.36 Mil (As of Jun. 2023)
Scopus BioPharma's quarterly cash, cash equivalents, marketable securities increased from Dec. 2022 ($0.13 Mil) to Mar. 2023 ($1.40 Mil) but then stayed the same from Mar. 2023 ($1.40 Mil) to Jun. 2023 ($0.36 Mil).
Scopus BioPharma's annual cash, cash equivalents, marketable securities increased from Dec. 2020 ($1.83 Mil) to Dec. 2021 ($7.94 Mil) but then declined from Dec. 2021 ($7.94 Mil) to Dec. 2022 ($0.13 Mil).
Scopus BioPharma Cash, Cash Equivalents, Marketable Securities Historical Data
The historical data trend for Scopus BioPharma's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
| Scopus BioPharma Annual Data | ||||||||||||
| Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | ||||||
| Cash, Cash Equivalents, Marketable Securities | Array( [0] => - [1] => - [2] => 0.04 [3] => 1.83 [4] => 7.94 [5] => 0.13)- | 0.04 | 1.83 | 7.94 | 0.13 | |||||||
| Scopus BioPharma Quarterly Data | ||||||||||||||||||||
| Jun18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
| Cash, Cash Equivalents, Marketable Securities | 1.16 | 0.31 | 0.13 | 1.40 | 0.36 | |||||||||||||||
Scopus BioPharma Cash, Cash Equivalents, Marketable Securities Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Scopus BioPharma(OTCPK:SCPS) Cash, Cash Equivalents, Marketable Securities Explanation
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Scopus BioPharma Cash, Cash Equivalents, Marketable Securities Related Terms
Thank you for viewing the detailed overview of Scopus BioPharma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Scopus BioPharma (Scopus BioPharma) Business Description
Industry
GURUFOCUS.COM »STOCK LIST »Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » Cash, Cash Equivalents, Marketable Securities
Comparable Companies
AMPE DRMA SPRC GSTC INM BXRX NBRVF SONN PKBO ADTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Website
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Executives
| Ira Scott Greenspan | director | 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106 |
| Joshua R Lamstein | director, officer: Chairman | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170 |
| Alan M Horsager | officer: See Remarks | 1021 N EVERETT STREET, GLENDALE CA 91207 |
| Robert J Gibson | director, officer: Vice Chairman | 71 LANTERN RIDGE RD, NEW CANAAN CT 06840 |
| Lesley Russell | director | 41 MOORES RD., FRAZER PA 19355 |
| Iv David Weild | director | 22 ORIOLE AVENUE, BRONXVILLE NY 10708 |
| David S. Battleman | director | C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019 |
| David A. Buckel | director | SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601 |
| Raphael Hofstein | director | C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120 |
| Paul Hopper | director | 7982 DOUG HILL, SAN DIEGO CA 92127 |
| Ashish P Sanghrajka | director, officer: President | 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005 |
Scopus BioPharma (Scopus BioPharma) Headlines
From GuruFocus
Scopus BioPharma Launches Duet Therapeutics
By Marketwired Marketwired • 09-02-2021
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
By Marketwired Marketwired • 10-08-2021
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
By GuruFocusNews GuruFocusNews • 05-05-2022
Scopus BioPharma's Subsidiary � Duet Therapeutics � to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
By Marketwired Marketwired • 09-22-2021
Scopus BioPharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
By Marketwired Marketwired • 09-09-2021
Scopus BioPharma's Subsidiary -- Duet BioTherapeutics -- Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
By Marketwired • 11-07-2023
DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS
By PRNewswire PRNewswire • 01-06-2022
Scopus BioPharma's Subsidiary � Duet Therapeutics � Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
By Marketwired Marketwired • 09-28-2021
By GuruFocusNews GuruFocusNews • 03-23-2022
Scopus BioPharma's Subsidiary � Duet Therapeutics � Announces Appointments of John Rossi, Ph.D. and Nagy Habib, Ch.M., F.R.C.S. to the Scientific Advisory Board
By Marketwired Marketwired • 09-14-2021
